Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26N4O2.CH4O3S |
Molecular Weight | 462.562 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=C(C)N2C=C(C=C(NCC3=C(C)C=CC=C3C)C2=N1)C(=O)NCCO
InChI
InChIKey=QCHUWMQLRFKFDK-UHFFFAOYSA-N
InChI=1S/C21H26N4O2.CH4O3S/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25;1-5(2,3)4/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27);1H3,(H,2,3,4)
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C21H26N4O2 |
Molecular Weight | 366.4567 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Linaprazan is a member of a new group of acid-suppressing agents, which unlike proton pump inhibitors, act through potassium-competitive inhibition of the H+,K+-ATPase located in the apical membrane of parietal cells. It displayed rapid inhibition of acid production and had a prolonged, dose-dependent duration of effect. Linaprazan reduced porcine renal Na(+),K(+)-ATPase activity by 9+/-2%, demonstrating a high selectivity for H(+),K(+)-ATPase. It provided similar efficacy to esomeprazole in terms of esophagitis healing and heartburn control.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17081503 |
0.13 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression. | 2012 Sep |
|
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. | 2014 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18184117
25, 50, 75 mg given once daily for 4 weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:28 GMT 2023
by
admin
on
Fri Dec 15 15:34:28 GMT 2023
|
Record UNII |
5P098C89CG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5P098C89CG
Created by
admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
|
PRIMARY | |||
|
11248232
Created by
admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
|
PRIMARY | |||
|
300000027093
Created by
admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
|
PRIMARY | |||
|
855998-67-3
Created by
admin on Fri Dec 15 15:34:28 GMT 2023 , Edited by admin on Fri Dec 15 15:34:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |